Cadrenal Therapeutics
CVKD
10 hedge funds and large institutions have $215K invested in Cadrenal Therapeutics in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
400% more funds holding
Funds holding: 2 → 10 (+8)
0.83% more ownership
Funds ownership: 0% → 0.84% (+0.83%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$152K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$31.4K |
| 3 |
Morgan Stanley
New York
|
+$16.6K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$7.22K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$5.32K |
Top Sellers
CVKD Hedge Fund Activity: Q4 2024 in Review
10 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q4 2024, worth a combined $215K — up 316,760% from $68 a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CVKD positions and 1 closed out — a net gain of 8 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $152K.
- 10 institutional investors held Cadrenal Therapeutics (CVKD) as of Q4 2024, up from 2 in Q3 2024.
- Funds reported $215K of Cadrenal Therapeutics stock for Q4 2024, up 316,760% quarter-over-quarter.
- 9 funds opened new Cadrenal Therapeutics positions in Q4 2024 and 1 closed out, a net change of +8 holders.
- The largest Cadrenal Therapeutics buyer in Q4 2024 was Geode Capital Management, an estimated $152K added.
Based on aggregated 13F filings for Q4 2024.